State of New Jersey Common Pension Fund D Sells 42,451 Shares of Ultragenyx Pharmaceutical Inc. $RARE

State of New Jersey Common Pension Fund D lessened its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 58.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 29,604 shares of the biopharmaceutical company’s stock after selling 42,451 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Ultragenyx Pharmaceutical were worth $681,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Assetmark Inc. boosted its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares during the period. Huntington National Bank lifted its stake in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares during the period. Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at approximately $39,000. Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares in the last quarter. Finally, Covestor Ltd grew its position in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 369 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Guggenheim dropped their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a report on Friday. Barclays cut their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Finally, Wall Street Zen downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.41.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the sale, the chief financial officer owned 110,342 shares of the company’s stock, valued at $2,747,515.80. The trade was a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president owned 76,346 shares in the company, valued at $1,740,688.80. The trade was a 9.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 111,522 shares of company stock valued at $2,543,214. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $26.30 on Tuesday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The firm’s 50-day simple moving average is $22.81 and its 200 day simple moving average is $26.68. The stock has a market cap of $2.59 billion, a PE ratio of -4.30 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter last year, the company earned ($1.57) EPS. The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.61 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.